Co-Chairs
Dr. Sharlene Gill
Dr. Nancy Nixon
Speakers
Dr. Manik Chahal
Studies/trials discussed:
- Vorasidenib in IDH1or IDH2-Mutant Low-Grade Glioma
- INDIGO: A global, randomized, double-blinded, phase 3 study of vorasidenib versus placebo in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation.
